Drug intelligence / Profile preview

Accum-T-DM1

Development stage: Preclinical
Lead developer: Defence Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

Accum-T-DM1 is an antibody-drug conjugate (ADC) developed by Defence Therapeutics. It is enhanced with Defence's proprietary ACCUM technology and is designed to improve upon the limitations of T-DM1 (Kadcyla®) in treating metastatic HER2-positive breast cancer. The drug aims to achieve enhanced efficacy and lower side effects compared to T-DM1.

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Accum-T-DM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accum-T-DM1.

Explore the full profile